title: [Efficacy of the dipeptide N(2)-L-Alanyl-L-glutamine in traumatic patients admitted to the ICU: a prospective, randomized, double-blind, multicentre study].
abstract: OBJECTIVE
  the endovenous administration of glutamine, independently of the type of nurtrition received, can reduce the ICU length of stay, the incidence of infections and the mortality in the traumatic patients admitted to the ICU.
  
  
  OBJECTIVE
  The main objective is to assess the efficacy of glutamine suplementation, given intravenously, to reduce the incidence of infectious complications, mortality and ICU length of stay in the traumatic patients admitted to the ICU. Other objectives are: 1) to assess the efficacy of glutamine in different groups of patients according to the severity and the plasma levels of glutamine. 2) Record all the adverse events due to the intravenous administration of glutamine.
  
  
  METHODS
  prospective, randomized, doble-blind and multicenter study with two parallel groups: placebo and treatment group. The patients who fulfill the inclusion criteria will receive either glutamine or placebo, independently of the type on nutrition. Glutamine will be administered as a pharmaconutrient at 0.5 g/kg/day during 5 days as a continous perfusion.
authors.affiliation: Servicio de Medicina Intensiva, Hospital Universitario Son Espases, Palma de Mallorca, España. juan.perez@ssib.es
authors.forename: J
authors.initials: J
authors.lastname: Pérez-Bárcena
authors.forename: P
authors.initials: P
authors.lastname: Marsé
authors.forename: M
authors.initials: M
authors.lastname: Cervera
authors.forename: G
authors.initials: G
authors.lastname: Frontera
authors.forename: J A
authors.initials: JA
authors.lastname: Llompart-Pou
authors.forename: J M
authors.initials: JM
authors.lastname: Raurich
authors.forename: A
authors.initials: A
authors.lastname: García de Lorenzo
mesh_terms: D000328:Adult; D000368:Aged; D003422:Critical Care; D004151:Dipeptides / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D005973:Glutamine / Q000097:blood; D006801:Humans; D017053:Infection Control; D007262:Infusions, Intravenous; D007362:Intensive Care Units; D007902:Length of Stay; D008297:Male; D008875:Middle Aged; D018529:Nutritional Support; D011446:Prospective Studies; D014947:Wounds and Injuries / Q000150:complications / Q000188:drug therapy* / Q000401:mortality; D055815:Young Adult
chemical_list: D004151:Dipeptides; D005973:Glutamine; C054122:alanylglutamine